HTLV-1 induces an inflammatory CD4+CD8+ T cell population in HTLV-1-associated myelopathy
File(s)
Author(s)
Type
Journal Article
Abstract
Human T cell leukemia virus type 1 (HTLV-1) is a retrovirus with preferential CD4+ T cell tropism that causes a range of conditions spanning from asymptomatic infection to adult T-cell leukemia and HTLV-1-associated myelopathy (HAM), an inflammatory disease of the CNS. The mechanisms by which HTLV-1 induces HAM are poorly understood. By directly examining the ex vivo phenotype and function of T cells from asymptomatic carriers and patients with HAM, we show that patients with HAM have a higher frequency of CD4+CD8+ double positive (DP) T cells, which are infected with HTLV-1 at higher rates than CD4+ T cells. Displaying both helper and cytotoxic phenotypes, these DP T cells are highly pro-inflammatory and contain high frequencies of HTLV-1-specific cells. Mechanistically, we demonstrate that DP T cells arise by direct HTLV-1 infection of CD4+ and CD8+ T cells. High levels of CD49d and CXCR3 expression suggest that DP T cells possess the ability to migrate to the CNS, and when co-cultured with astrocytes, DP T cells induce proinflammatory astrocytes that express high levels of CXCL10, IFN-, and IL-6. These results demonstrate the potential of DP T cells to directly contribute to CNS pathology.
Date Issued
2024-01-09
Date Acceptance
2023-11-15
Citation
Journal of Clinical Investigation Insight, 2024, 9 (1)
ISSN
0021-9738
Publisher
American Society for Clinical Investigation
Journal / Book Title
Journal of Clinical Investigation Insight
Volume
9
Issue
1
Copyright Statement
Copyright: © 2024, Maher et
al. This is an open access article
published under the terms of the
Creative Commons Attribution 4.0
International License.
al. This is an open access article
published under the terms of the
Creative Commons Attribution 4.0
International License.
License URL
Identifier
https://insight.jci.org/articles/view/173738
Publication Status
Published
Article Number
e173738
Date Publish Online
2024-01-09